Wealthspire Advisors LLC Has $1.12 Million Stake in Danaher Co. (NYSE:DHR)

Wealthspire Advisors LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 9.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,829 shares of the conglomerate’s stock after selling 522 shares during the quarter. Wealthspire Advisors LLC’s holdings in Danaher were worth $1,117,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nicholas Hoffman & Company LLC. raised its holdings in shares of Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after acquiring an additional 43 shares during the period. Los Angeles Capital Management LLC boosted its position in Danaher by 1.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock worth $803,000 after acquiring an additional 43 shares during the last quarter. Drive Wealth Management LLC raised its holdings in shares of Danaher by 3.1% in the fourth quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after purchasing an additional 44 shares during the last quarter. Mission Wealth Management LP increased its stake in Danaher by 0.4% in the 4th quarter. Mission Wealth Management LP now owns 10,888 shares of the conglomerate’s stock valued at $2,519,000 after buying an additional 46 shares during the last quarter. Finally, Trust Investment Advisors grew its holdings in shares of Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after acquiring an additional 49 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Up 1.1 %

Shares of NYSE DHR traded up $2.72 during midday trading on Friday, reaching $254.15. The stock had a trading volume of 149,620 shares, compared to its average volume of 2,689,130. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The company’s 50 day moving average price is $248.15 and its 200 day moving average price is $233.30. The firm has a market cap of $188.25 billion, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 3.82 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the firm posted $2.36 earnings per share. The firm’s revenue was down 2.6% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. Danaher’s dividend payout ratio is presently 18.31%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Royal Bank of Canada boosted their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Barclays increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Insider Buying and Selling

In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 103,984 shares of company stock valued at $25,997,094. 10.90% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.